Britain’s biotech firms now have a code of conduct designed to prevent them
from overhyping the progress of experimental drugs. Published this week by the
BioIndustry Association (BIA), the code was drafted in the wake of a damaging
scandal last year
(This Week, 4 July 1998, p 20).
From now on, companies must
have their scientific and clinical progress audited by external experts. Failure
to comply could mean expulsion from the BIA.
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Fermat's Last Theorem: still a must-read about a 350-year maths secret
2
We might finally know how to use quantum computers to boost AI
3
Table tennis-playing robot on track to becoming world champion
4
Exercise advice for long covid may be doing more harm than good
5
The monstrous number sequences that break the rules of mathematics
6
Why quantum physics says there’s a multiverse
7
Why your opinion of used electric vehicles is probably wrong
8
Security credentials inadvertently leaked on thousands of websites
9
Why aren't young people having sex any more?
10
How to spot the Lyrid meteor shower tonight
